Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...
drugtargetreview.com6 天
CN Bio advances hepatotoxicity testing to reduce drug failures
CN Bio enhances hepatotoxicity testing to improve drug safety, reducing the risk of costly clinical trial failures.